Head And Neck Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 3 PAGES: 341

More Info
									       Head And Neck Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1724IDB
                                                                                           Publication Date: February 2012




Head And Neck Cancer – Pipeline Review, H1 2012                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Head And Neck Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 12
    List of Figures .............................................................................................................................................................................. 16
Introduction....................................................................................................................................................................................... 17
    Global Markets Direct Report Coverage ...................................................................................................................................... 17
Head And Neck Cancer Overview .................................................................................................................................................... 18
Therapeutics Development............................................................................................................................................................... 19
    An Overview of Pipeline Products for Head And Neck Cancer .................................................................................................... 19
Head And Neck Cancer Therapeutics under Development by Companies ...................................................................................... 21
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes ....................................................................... 27
Late Stage Products ......................................................................................................................................................................... 40
    Comparative Analysis .................................................................................................................................................................. 40
Mid Clinical Stage Products.............................................................................................................................................................. 41
    Comparative Analysis .................................................................................................................................................................. 41
Early Clinical Stage Products ........................................................................................................................................................... 42
    Comparative Analysis .................................................................................................................................................................. 42
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 43
    Comparative Analysis .................................................................................................................................................................. 43
Head And Neck Cancer Therapeutics – Products under Development by Companies .................................................................... 44
Head And Neck Cancer Therapeutics – Products under Investigation by Universities/Institutes ..................................................... 51
Companies Involved in Head And Neck Cancer Therapeutics Development ................................................................................... 83
    Johnson & Johnson ..................................................................................................................................................................... 83
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 84
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 85
    Amgen Inc. .................................................................................................................................................................................. 86
    Sanofi-Aventis ............................................................................................................................................................................. 87
    AstraZeneca PLC ........................................................................................................................................................................ 88
    Eli Lilly and Company .................................................................................................................................................................. 89
    Viralytics Ltd. ............................................................................................................................................................................... 90
    GlaxoSmithKline plc .................................................................................................................................................................... 91
    YM BioSciences Inc..................................................................................................................................................................... 92
    Symphogen A/S........................................................................................................................................................................... 93
    Light Sciences Oncology, Inc. ..................................................................................................................................................... 94
    Celltrion, Inc................................................................................................................................................................................. 95
    Bio-Path Holdings, Inc. ................................................................................................................................................................ 96
    Aposense Ltd............................................................................................................................................................................... 97
    Millennium Pharmaceuticals, Inc. ................................................................................................................................................ 98
    Novartis AG ................................................................................................................................................................................. 99
    ImClone Systems Incorporated ................................................................................................................................................. 100
    Daewoong Pharmaceutical Co., Ltd. ......................................................................................................................................... 101
    Eisai Co., Ltd. ............................................................................................................................................................................ 102
    Pfizer Inc.................................................................................................................................................................................... 103



Head And Neck Cancer – Pipeline Review, H1 2012                                                                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Head And Neck Cancer – Pipeline Review, H1 2012




    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 104
    Takara Holdings Inc................................................................................................................................................................... 105
    Cyclacel Pharmaceuticals Inc. ................................................................................................................................................... 106
    CEL-SCI Corporation................................................................................................................................................................. 107
    Quintiles Transnational Corp. .................................................................................................................................................... 108
    SRI International ........................................................................................................................................................................ 109
    Merck KGaA .............................................................................................................................................................................. 110
    Advaxis, Inc. .............................................................................................................................................................................. 111
    Neogenix Oncology Corporation................................................................................................................................................ 112
    InNexus Biotechnology Inc. ....................................................................................................................................................... 113
    Idera Pharmaceuticals, Inc. ....................................................................................................................................................... 114
    NexMed, Inc. ............................................................................................................................................................................. 115
    Northwest Biotherapeutics, Inc. ................................................................................................................................................. 116
    Cleveland BioLabs, Inc. ............................................................................................................................................................. 117
    Oncolytics Biotech Inc. .............................................................................................................................................................. 118
    Oncothyreon Inc ........................................................................................................................................................................ 119
    Curis, Inc. .................................................................................................................................................................................. 120
    Transgene SA............................................................................................................................................................................ 121
    Jiangsu Hengrui Medicine Co., Ltd. ........................................................................................................................................... 122
    Nang Kuang Pharmaceutical Co., Ltd. ...................................................................................................................................... 123
    PCI Biotech AS .......................................................................................................................................................................... 124
    Piramal Life Sciences Limited.................................................................................................................................................... 125
    Avanti Therapeutics ................................................................................................................................................................... 126
    Wilex AG ................................................................................................................................................................................... 127
    Acceleron Pharma, Inc. ............................................................................................................................................................. 128
    Glycotope GmbH ....................................................................................................................................................................... 129
    Hawthorn Pharmaceuticals, Inc. ................................................................................................................................................ 130
    PDS Biotechnology Corporation ................................................................................................................................................ 131
    Merrimack Pharmaceuticals, Inc................................................................................................................................................ 132
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 133
    Innogene Kalbiotech Pte Ltd...................................................................................................................................................... 134
    Vaccinogen, Inc. ........................................................................................................................................................................ 135
    Oncolys BioPharma Inc. ............................................................................................................................................................ 136
    Etubics Corporation ................................................................................................................................................................... 137
    Viventia Biotechnologies Inc. ..................................................................................................................................................... 138
    IRX Therapeutics, Inc. ............................................................................................................................................................... 139
    Pique Therapeutics.................................................................................................................................................................... 140
    Cellceutix Pharmaceuticals, Inc. ................................................................................................................................................ 141
    PNP Therapeutics, Inc............................................................................................................................................................... 142
    Eurofarma .................................................................................................................................................................................. 143
    TAU Therapeutics, LLC ............................................................................................................................................................. 144
    Boneca Corporation................................................................................................................................................................... 145
    Biotech Pharmaceuticals Co., Ltd.............................................................................................................................................. 146
    CytomX, LLC. ............................................................................................................................................................................ 147


Head And Neck Cancer – Pipeline Review, H1 2012                                                                                            GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Head And Neck Cancer – Pipeline Review, H1 2012




Head And Neck Cancer – Therapeutics Assessment..................................................................................................................... 148
    Assessment by Monotherapy Products ..................................................................................................................................... 148
    Assessment by Combination Products ...................................................................................................................................... 149
    Assessment by Route of Administration .................................................................................................................................... 150
    Assessment by Molecule Type .................................................................................................................................................. 153
Drug Profiles................................................................................................................................................................................... 156
    Sotatercept - Drug Profile .......................................................................................................................................................... 156
        Product Description............................................................................................................................................................... 156
        Mechanism of Action ............................................................................................................................................................. 156
        R&D Progress ....................................................................................................................................................................... 156
    Multikine - Drug Profile .............................................................................................................................................................. 158
        Product Description............................................................................................................................................................... 158
        Mechanism of Action ............................................................................................................................................................. 158
        R&D Progress ....................................................................................................................................................................... 158
    Tykerb - Drug Profile ................................................................................................................................................................. 160
        Product Description............................................................................................................................................................... 160
        Mechanism of Action ............................................................................................................................................................. 160
        R&D Progress ....................................................................................................................................................................... 160
    Tirazone - Drug Profile .............................................................................................................................................................. 161
        Product Description............................................................................................................................................................... 161
        Mechanism of Action ............................................................................................................................................................. 161
        R&D Progress ....................................................................................................................................................................... 161
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 162
        Product Description............................................................................................................................................................... 162
        Mechanism of Action ............................................................................................................................................................. 162
        R&D Progress ....................................................................................................................................................................... 162
    Tarceva - Drug Profile ............................................................................................................................................................... 163
        Product Description............................................................................................................................................................... 163
        Mechanism of Action ............................................................................................................................................................. 163
        R&D Progress ....................................................................................................................................................................... 163
    Proxinium - Drug Profile ............................................................................................................................................................ 165
        Product Description............................................................................................................................................................... 165
        Mechanism of Action ............................................................................................................................................................. 165
        R&D Progress ....................................................................................................................................................................... 165
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 167
        Product Description............................................................................................................................................................... 167
        Mechanism of Action ............................................................................................................................................................. 167
        R&D Progress ....................................................................................................................................................................... 167
    Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile ..................................................................................................... 169
        Product Description............................................................................................................................................................... 169
        Mechanism of Action ............................................................................................................................................................. 169
        R&D Progress ....................................................................................................................................................................... 169
    Taxotere + Cisplatin + 5-Fluorouracil + Carboplatin + Radiation Therapy - Drug Profile ........................................................... 170
        Product Description............................................................................................................................................................... 170


Head And Neck Cancer – Pipeline Review, H1 2012                                                                                           GMDHC1724IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(4)
Head And Neck Cancer – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................. 170
        R&D Progress ....................................................................................................................................................................... 171
    Carboplatin + Radiotherapy - Drug Profile ................................................................................................................................. 172
        Product Description............................................................................................................................................................... 172
        Mechanism of Action ............................................................................................................................................................. 172
        R&D Progress ....................................................................................................................................................................... 172
    Gefitinib - Drug Profile ............................................................................................................................................................... 173
        Product Description............................................................................................................................................................... 173
        Mechanism of Action ............................................................................................................................................................. 173
        R&D Progress ....................................................................................................................................................................... 173
    Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile ................................................................................................... 175
        Product Description............................................................................................................................................................... 175
        Mechanism of Action ............................................................................................................................................................. 175
        R&D Progress ....................................................................................................................................................................... 175
    Cisplatin + Xeloda + Radiation Therapy - Drug Profile .............................................................................................................. 177
        Product Description............................................................................................................................................................... 177
        Mechanism of Action ............................................................................................................................................................. 177
        R&D Progress ....................................................................................................................................................................... 178
    Cisplatin + Cetuximab + Radiation Therapy - Drug Profile ........................................................................................................ 179
        Product Description............................................................................................................................................................... 179
        Mechanism of Action ............................................................................................................................................................. 179
        R&D Progress ....................................................................................................................................................................... 179
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................. 181
        Product Description............................................................................................................................................................... 181
        Mechanism of Action ............................................................................................................................................................. 181
        R&D Progress ....................................................................................................................................................................... 181
    Cisplatin + Docetaxel + Fluorouracil + Bevacizumab - Drug Profile .......................................................................................... 182
        Product Description............................................................................................................................................................... 182
        Mechanism of Action ............................................................................................................................................................. 182
        R&D Progress ....................................................................................................................................................................... 182
    Erbitux + Carboplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile ................................................................................ 184
        Product Description............................................................................................................................................................... 184
        Mechanism of Action ..........................................................................................................................................
								
To top